Developmental Toxicity of 2,3,4,7,8-Pentachlorodibenzofuran in the Fischer 344 Flat

Developmental Toxicity of 2,3,4,7,8-Pentachlordibenzofuran inthe Fischer 344 Rat. COUTURE, L. A,, HARRIS, M. W., AND BIRNBAUM,L. S. (1989). Fundam Appl Toxicol 12, 358–366. Fischer344 rats were exposed acutely to 2,3,4,7,8-pentachlordibenzofuran(4-PeCDF) during the organogenic period to evaluate its potentialas an inducer of teratogenic and embryolethal effects. All damswere treated by gavage with a single dose of 0, 30, 100, or300 µg 4- PeCDF/kg body wt on gestation Day (gd) 8, 10,or 12. An additional treatment group was included on gd 12 andadministered 10µg 4-PeCDF/kg body wt po. All animals werekilled on gd 20 and maternal and fetal toxicities were assessed.Determination of embryotoxicity involved both soft tissue andskeletal examinations. 4-PeCDF induced a dose-related decreasein corrected maternal weight gain following treatment on gd8 and 10, as well as resulted in a concomitant Increase in theliver/body weight ratios, first evident at 30 µg/kg forall 3 days of exposure. The maternal thymus weight decreasedrelative to body weight compared with those of controls. Embryo-fetaltoxicity was evident from the high mortality (>80%) observedat 300 µg/kg for all 3 days of exposure. Mean fetal weight,a sensitive indicator of fetal toxicity, decreased comparedto that of controls at 30, 100, and 300 µg/kg followingtreatment on either gd 8, 10, or 12. 4- PeCDF induced cleftpalate in survivors at a dose of 300 µg/kg for all 3 daysof exposure. In conclusion, 4-PeCDF is maternally and fetallytoxic regardless of the gestation day of exposure, but inducedterata only at doses where overt maternal and fetal toxicitywere observed, in contrast to previously reported studies inthe mice where teratogenic effects were observed at nonfetotoxicdose levels. Thus, the mouse may be a more sensitive model forevaluating specific toxic responses induced prenatally followingexposure to the structurally related polyhalogenated aromatichydrocarbons which include the dioxins, furans, biphenyls, andnaphthalenes.     

Disposition and excretion of 2,3,4,7,8-pentachlorodibenzofuran in the rat

The disposition of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF), a highly toxic environmental contaminant which accumulates in human tissues, was examined in the male Fischer rat after iv and oral exposure. Greater than 70% of an oral dose of 0.1, 0.5, or 1.0 mumol PeCDF/kg body wt was absorbed by the gastrointestinal system. After either oral or iv administration of 0.1 mumol/kg, the dibenzofuran was rapidly removed from the blood and accumulated in the liver and adipose tissue and to a lesser extent in the skin and muscle. Three days after administration, 70% of the iv dose of PeCDF was found in the liver, 7% in the fat, 1% in the skin, and 0.5% in the muscle. Route of exposure had little effect on tissue distribution. TLC analyses indicated that greater than 99% of the [14C]-PeCDF-derived radioactivity which had accumulated in the liver and adipose tissue was unmetabolized PeCDF which was eliminated very slowly (t1/2 = 193 and 69 days, respectively). The whole body half-life calculated from the daily fecal excretion rate was approximately 64 days. Excretion occurred primarily via the feces. No radioactivity was detected in expired air and less than 0.02% was detected in the urine. TLC analysis of fecal extracts indicated greater than 90% of the [14C]PeCDF-derived radioactivity in the feces was polar metabolites of the parent compound. Pretreatment with 500 micrograms PeCDF/kg body wt caused biliary excretion to nearly double. Treatment of bile with beta-glucuronidase or arylsulfatase had little effect on the chromatographic profile. Therefore, PeCDF was readily absorbed from the gastrointestinal tract, concentrated primarily in the liver, and was slowly eliminated from the body as polar metabolites. The long half-life and high body burden of PeCDF suggest that the toxicity of this chemical may be enhanced due to bioaccumulation upon chronic low-level exposure.     

Subchronic peroral toxicity of triethylene glycol in the Fischer 344 rat

Ethylene and diethylene glycols produce systemic toxicity, including nephrotoxicity, by acute and repeated po dosing. To determine the potential for triethylene glycol (TEG; CAS Number 112-27-61) to produce nephrotoxicity, or other organ/tissue injury, a subchronic (90-d) study was conducted by continuous inclusion of TEG in the diet of Fischer 344 rats. This was preceded by a probe 14-d study. For both studies the dietary concentrations were 0 ppm (control), 10,000, 20,000 or 50,000 ppm TEG, resulting in daily TEG consumptions in the 14-d study of 1132, 2311 or 5916 mg/kg with males, and 1177, 2411 or 6209 mg/kg with females. The corresponding values for the 90-d study were 748, 1522 or 3849 mg/kg (males), and 848, 1699 or 4360 mg/kg (females). In the 14-d study there were no mortalities or clinical signs, and no effects on body weight, hematology, serum chemistry, organ weights, and gross or microscopic pathology. Food consumption was increased at the high dosage. Urinalysis showed increased urine volume and decreased pH with high dose males and females, and increased volume with mid-dose males. In the subchronic study there was neither mortality nor signs of toxicity, and no dosage-related effects with serum chemistry, gross and microscopic pathology. Body weights were reduced during the dosing period with both males and females of the high dosage. Body weight gains were reduced at all dosages with males and females. No hematological effects were seen with females, but males of the mid- and high-dosage groups had slightly reduced erythrocyte count and hematocrit, and high-dose males had decreased hemoglobin concentration with increased mean corpuscular volume. These were considered to reflect a mild hemodilution related to the absorption of large TEG doses. Urinalysis showed dosage-related decreased pH, and increased urine volume mainly at the high dose. These were probably related to the renal excretion of absorbed TEG and/or metabolites. Kidney weight was increased for high-dose females, and increased relative (to body) weight of kidneys for males and females from the mid- and high-dose groups were observed, probably related to the renal excretion of the absorbed TEG and/or its metabolites. These findings indicate that the subchronic continuous po dosing of TEG to rats does not result in local or systemic specific organ or tissue toxicity. These findings contrast with the known repeated po toxicity, notably nephrotoxicity, produced by ethylene and diethylene glycols. Thus, TEG has significantly lesser potential for systemic toxicity by the po route than its lower molecular weight homologues.     

Reproductive toxicity of dimethyl methyl phosphonate (DMMP) in the male Fischer 344 rat

Dimethyl methyl phosphonate (DMMP) has been considered for use by the U.S. Armed Forces as a nerve gas simulant in a variety of experimental situations to simulate the physical properties of nerve gases, but not the neurotoxic properties. Dimethyl methyl phosphonate is also used as a flame retardant for urethane foams and polyester resins. This study was conducted to determine the reproductive toxicity of DMMP after subchronic dosing. DMMP was administered to male Fischer 344 rats by gavage 5 days/week for 90 days at dosages of 0, 250, 500, 1000, and 2000 mg/kg, and all animals survived this dosing schedule. At Day 84, the rats were mated to untreated female Fischer 344 rats. There was a dose-related decrease in sperm count, sperm motility, and the male fertility index. The male fertility index was 70, 75, 60, 40, and 0% in the 0, 250, 500, 1000, and 2000 mg/kg dose groups. DMMP acted as a dominant lethal mutagen as demonstrated by an increase in the number of resorptions with increasing doses of the drug. The percentage of resorptions in the control group was 6.1% and increased to 14.9, 37.8, and 79.1% in the 250, 500, and 1000 mg/kg groups, respectively. The testes of the male rats were examined histologically to determine the relationship between reproductive function and pathologic abnormalities. DMMP altered reproductive function at all dose levels, while histologic abnormalities of the testis were seen only in the high-dose group. Changes in the testes of the high-dose animals were characterized by lack of spermatogenesis or by degeneration, vacuolization, and necrosis of cells in the spermatogenic tubules. Histopathologic abnormalities of the kidney were seen in some animals from each of the dosed groups and microscopic changes of the prostate were seen in some of the high-dose animals.     

Chronic toxicity of 1,3,5-trinitrobenzene in Fischer 344 rats

The chronic toxicity of 1,3,5-trinitrobenzene (TNB) in male and female Fischer 344 (F344) rats was evaluated by feeding a diet containing 0, 5, 60, and 300 ppm of TNB for 2 years. The calculated average TNB intake over 2 years for males and females was 0.22, 2.64, 13.44 and 0.23, 2.68, 13.31 mg/kg body weight (BW)/day respectively. Terminal body weights were decreased and water intake was increased in both sexes (300 ppm), whereas food consumption was decreased in males (60 and 300 ppm groups) only. The relative spleen weights were significantly decreased in both sexes (300 ppm), whereas the relative brain weights were increased in females only (300 ppm). Hematological effects were not observed in animals killed at the 2-year time point, except significant decrease in the mean corpuscular hemoglobin (MCH) in males (300 ppm) and in females (60 and 300 ppm). Methemoglobin levels were increased in both sexes in the high dose group. Histopathological examination showed treatment-related changes in the kidney (hyaline droplets; 60 and 300 ppm) and the spleen (erythroid cell hyperplasia and pigment deposition; 300 ppm) of both sexes. Cytoplasmic hyaline droplets in the kidneys were characterized by immunohistochemistry as alpha-2mu-globulin. We propose a chronic, oral no-observable-adverse-effect level (NOAEL) of 2.68 mg/kg BW/day for TNB in the rat, based on the hematological and renal changes.     

Subchronic toxicity of trinitrotoluene in Fischer 344 rats rats

This study was conducted to evaluate the toxicity of trinitrotoluene (TNT) in Fischer 344 rats when administered in the diet for 13 weeks. Groups of 10 rats per sex received TNT at doses of 1, 5, 25, 125 or 300 mg/kg/day. Thirty rats per sex served as untreated controls. Toxicologic endpoints included clinical signs, body weight, food consumption, hematology, clinical biochemistry, organ weights and gross/histopathology. Toxic effects following 125 mg/kg/day or greater included decreased food intake and body weight gain, elevated serum cholesterol levels, and anemia (reduced hemoglobin, hematocrit and RBC counts). Splenomegaly, hepatomegaly/hepatocytomegaly and testicular atrophy with degeneration of the seminiferous tubular epithelium were also seen at 125 and 300 mg/kg/day. Hemosiderin-laden macrophages, congestion of the splenic red pulp, methemoglobin production indicative of the oxidizing activity of TNT and/or its metabolites, and the lack of bone marrow toxicity suggested hemolysis as the mechanism of anemia.     

Developmental and behavioral effects of acrylamide in Fischer 344 rats

Human exposures to acrylamide (ACR), a known neurotoxicant, can occur via a variety of substances, including cigarette smoke and the ingestion of certain carbohydrate-based foods cooked at high temperatures. In this study, Fischer 344 sperm plug-positive female rats were treated daily with ACR (0, 0.5, 1.0, 2.5, 5.0 or 10.0 mg/kg/day) by gavage beginning on gestation day 7. Dosing of dams ended when litters were born; pups received daily gavage at the same dose as their dam from postnatal day (PND) 1 through PND22. Pups were tested using a battery of behavioral assessments from PNDs 4-22. Statistically significant decreases in body weight were observed in pups exposed to ACR at doses as low as 1.0 mg/kg/day (treatmentxday; repeated measures ANOVA, P<0.0001). No statistically significant differences among treatment groups were observed in righting reflex, forelimb hang, or open field measures of activity. Statistically significant effects of ACR were observed at the 10 mg/kg/day dose on negative geotaxis performance (P<0.01) and a linear trend in fall-time latencies on Rotarod performance on PNDs 21-22 (P<0.05), with higher doses producing shorter latencies. These results suggest that ACR exposure produces deficits in development and motor coordination that are observable before weaning.     

Stereochemical inversion of haloxyfop in the Fischer 344 rat

The 2-aryloxypropionate haloxyfop is currently being evaluated for use as a herbicide. This compound is structurally similar to a group of 2-arylpropionates that have been shown previously to undergo stereochemical inversion in a variety of mammalian species. To support the data obtained from a number of toxicity/oncongenicity studies, in which racemic haloxyfop was employed, the stereochemical disposition of this compound was examined in the Fischer 344 rat. After administration of racemic haloxyfop (11 mg/kg, po) to male and female Fischer 344 rats, the day 1-10 urine samples were fortified with D4-haloxyfop (center ring label) and extracted, and the haloxyfop enantiomers were converted to diastereomeric derivatives [(S)-phenylethylamine] and analyzed by gas chromatography-mass spectrometry (GC/MS). Fecal samples for days 1-10 were fortified with D4-haloxyfop, extracted, and purified by reverse phase high-pressure liquid chromatography prior to derivation and GC/MS analysis. In the female rat, 77.3% of the administered dose was recovered in the day 1-10 urine and feces as parent compound. The stereochemistry of the haloxyfop present in these samples was found to be nearly all (R)-enantiomer (greater than 98%). In the male rat, 52.2% of the dose was recovered in the day 1-10 urine and feces as haloxyfop. The stereochemistry of the parent compound present in these samples was similar to the results seen in the female rat [greater than 98% (R)]. These results show that (S)-haloxyfop undergoes rapid and nearly complete inversion to the (R)-enantiomer in the female Fischer 344 rat. The data also suggest a similar stereochemical inversion of haloxyfop in the male Fischer 344 rat.     

Renal and hepatic toxicity of N-arylsuccinimides in Fischer 344 rats

The role of aromaticity in the nephrotoxic potential of N-arylsuccinimides was studied in male Fischer 344 rats. Rats were administered a single intraperitoneal (i.p.) injection of an N-arylsuccinimide derivative (0.4 or 1.0 mmol/kg) or sesame oil (2.5 ml/kg), and the renal function monitored at 24 and 48 h. The parent compound in this series, N-phenylsuccinimide (NPS), had previously been shown to induce only minimal renal effects, having no effect on urine volume, blood urea nitrogen concentration, kidney weight, p-aminohippurate accumulation or renal morphology. Only an increase in tetraethylammonium uptake has been observed following NPS administration to rats. These effects were not enhanced by reducing aromaticity (N-cyclohexylsuccinimide (NCS]. Compounds with increased aromaticity N-(1-naphthyl)succinimide (NNS), N-(1-anthracenyl)succinimide (1-NAS) and N-(9-anthracenyl)succinimide (9-NAS)--also only weakly affected renal function. However, NNS (1.0 mmol/kg) and, to a lesser degree, 9-NAS (1.0 mmol/kg) proved to be hepatotoxins. Liver damage was most pronounced near central vein regions of the lobule and least evident around periportal sites. Damaged liver tissue exhibited unusually large deposits of connective tissue and hypertrophied hepatocytes with numerous vacuoles in their cytoplasm. Therefore, derivatives of NPS with increased or decreased aromaticity relative to the parent compound do not exhibit the ability to induce moderate or marked nephrotoxicity. However, increasing aromaticity did produce the derivatives NNS and 9-NAS, which are hepatotoxins. These compounds represent the first members in this series of compounds to induce acute hepatotoxicity.     

Inhalation Developmental Toxicity Study of Propylene Oxide in Fischer 344 Rats

The developmental toxicity potential of propylene oxide (PO)was evaluated in Fischer 344 rats following inhalation exposure.Four groups of 25 mated female rats were exposed to 0, 100,300, and 500 ppm of PO for 6 hr per day on Gestation Days 6through 15, inclusive. Cesarean sections were performed on allfemales on Gestation Day 20 and the fetuses removed for morphologicalevaluation. Exposure to propylene oxide did not adversely affectsurvival, appearance, or behavior at any of the exposure levelstested. Maternal body weight gain and food consumption werereduced significantly among the females at the 500 ppm levelduring the exposure period. No exposure-related effects werenoted with respect to maternal water consumption, organ weights,cesarean section, or fetal morphological observations with thesole exception of increased frequency of seventh cervical ribsin fetuses at the maternally toxic exposure level of 500 ppm.In summation, the no-observable-adverse-effect level (NOAEL)of propylene oxide. when administered to Fischer 344 rats viawhole-body inhalation exposure, was considered to be 300 ppm.     

Developmental Exposure to Lead Causes Persistent Immunotoxicity in Fischer 344 Rats

Lead has been shown to exert toxic effects during early development.In these in vivo and ex vivo experiments, the effect of leadon the immune system of the developing embryo was assessed.Nine-week-old female Fischer 344 rats were exposed to lead acetate(0,100,250, and 500 ppm lead) in their drinking water duringbreeding and pregnancy (exposure was discontinued at parturition).Offspring received no additional lead treatment after birth.Immune function was assessed in female offspring at 13 weeksof age. Dams in lead-exposed groups were not different fromcontrols with respect to the immune endpoints used in theseexperiments; however, in the offspring, lead modulated importantimmune parameters at modest exposure levels. Macrophage cytokineand effector function properties (tumor necrosis factor-     

Chronic toxicity and carcinogenicity studies of olestra in Fischer 344 rats

Two 2-year feeding studies were carried out in Fischer 344 rats with olestra, a mixture of the hexa-, hepta- and octaesters of sucrose formed with long-chain fatty acids. Olestra was fed at 0, 0.99, 4.76 or 9.09% (w/w) of the diet in the first study, and at 0 or 9.09% (w/w) of the diet in the second. Daily observations, feed consumption and body weights, ophthalmoscopic examinations, organ weights, serum chemistry, haematology, urinalysis and histopathological evaluations revealed no evidence of any adverse effects associated with olestra ingestion. Relative to controls, there was a higher incidence of basophilic liver foci in olestra-fed female rats at 12 months. At 24 months, foci were observed in most animals in all groups but were more numerous in olestra-fed females. The foci were not associated with hepatic tumours, alterations in liver function, or increases in liver weight and therefore not considered to represent a toxic response to olestra. Isolated statistically significant differences in mortality, mononuclear cell leukaemia, and pituitary adenomas were observed but were not considered to be related to olestra ingestion since they were not reproducible across the two studies, generally not dose responsive, not consistent between sexes, and the incidences were within the ranges for historical and contemporary laboratory controls. The results of the two studies show that olestra was not toxic or carcinogenic when fed to rats at up to 9% of the diet for 24 months.     

Disposition and metabolism of isoeugenol in the male Fischer 344 rat

The primary objective of these studies was to determine the absorption, distribution, metabolism and excretion of isoeugenol following oral and intravenous administration to male Fischer-344 rats. Following a single oral dose of [¹⁴C]isoeugenol (156 mg/kg, 50 μCi/kg), greater than 85% of the administered dose was excreted in the urine predominantly as sulfate or glucuronide metabolites by 72 h. Approximately 10% was recovered in the feces, and less than 0.1% was recovered as CO₂ or expired organics. No parent isoeugenol was detected in the blood at any of the time points analyzed. Following iv administration (15.6 mg/kg, 100 μCi/kg), isoeugenol disappeared rapidly from the blood. The t_1/2 was 12 min and the Cl_s was 1.9 l/min/kg. Excretion characteristics were similar to those of oral administration. The total amount of radioactivity remaining in selected tissues by 72 h was less than 0.25% of the dose following either oral or intravenous administration. Results of these studies show that isoeugenol is rapidly metabolized and is excreted predominantly in the urine as phase II conjugates of the parent compound.     

Disposition and pharmacokinetics of inhaled dimethylamine in the Fischer 344 rat

The disposition and pharmacokinetics of [14C]dimethylamine [( 14C] DMA) following 6-hr inhalation of either 10 or 175 ppm were determined in male Fischer 344 rats. Seventy-two hours after termination of exposure, the disposition of recovered radioactivity was similar for each airborne concentration, with more than 90% in the urine and feces, 7 to 8% in selected tissues and the carcass, and 1.5% exhaled as 14CO2. Over 98% of the radioactivity in the urine was unmetabolized DMA. Analysis of tissue radioactivity immediately after exposure to [14C]DMA showed that the respiratory nasal mucosa contained the highest concentration of 14C, followed by the olfactory nasal mucosa; concentrations of 14C in liver, lung, kidney, brain, and testes were approximately 2 orders of magnitude less than in the nasal mucosal tissues. Radioactivity in plasma of rats exposed by inhalation to 175 ppm of [14C]DMA decayed in a biphasic manner. The terminal half-life for plasma radioactivity was similar to the half-lives of some plasma proteins, suggesting incorporation of 14C into proteins subsequent to metabolism of [14C]DMA. The results indicate that, while most of the inhaled DMA is excreted unchanged, a small amount of oxidative metabolism of DMA occurs.     

Effect of inhaled dimethylselenide in the Fischer 344 male rat.

In this project, a total of 60 adult Fischer 344 male rats were exposed to dimethylselenide (DMSe) vapor at 1607, 4499, or 8034 ppm for 1 h (20 rats/group). In addition, 26 unexposed rats were used as controls. The exposed rats were observed frequently during the 7 d following exposure and appeared normal. The animals were sacrificed at either 1 or 7 d after inhalation and the major tissues were grossly examined and weighed. Selenium levels were found to be elevated only in the lung at d 1. At d 1, significant changes in organ weights were an increase in the lung weight at exposure levels of 1607 and 8034 ppm of DMSe and in liver weight at 4499 and 8034 ppm. At d 1, significant changes in the lung were an increase in protein at 1607 and 8034 ppm of DMSe, and an increase in RNA and a reduction in DNA at 4499 ppm DMSe. The only change in the liver was a reduction in DNA at 4499 ppm. At 7 d, the protein content and RNA content of spleen were increased. Lung, liver, kidney, spleen, thymus, lymph nodes, pancreas, and adrenal gland were examined microscopically and found to be normal. All of these observed responses were minor and did not severely impact the health of the rats. Overall, the data indicate that the inhalation of DMSe for 1 h has relatively low toxicity in rats even at high concentrations.     

Recommended relative potency factors for 2,3,4,7,8-pentachlorodibenzofuran: the impact of different dose metrics.

The recent National Toxicology Program (NTP) cancer bioassays for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 2,3,4,7,8-pentachlorodibenzofuran (4-PeCDF) permit a reevaluation of the current TEF value of 4-PeCDF. The data also allow for the derivation of relative potency factors (RPFs) for cancer, which are based not only on administered dose but also on potentially more informative dose metrics, such as liver concentration, area under the liver concentration curve, and lifetime average body burden. Our analyses of these data indicate that chi-squared tests of observed versus predicted liver tumor incidence for 4-PeCDF reject the current TEF value of 0.5 value as too high. 4-PeCDF RPFs were derived using estimation methods that either did or did not assume parallelism of the 4-PeCDF and TCDD dose-response curves. The resulting parallelism-based RPFs for administered dose, liver concentration at terminal sacrifice, liver concentration AUC, and lifetime average body burden are 0.26, 0.014, 0.021, and 0.036, respectively. The administered dose RPF estimate is approximately one-half the current TEF value of 0.5. However, the use of administered dose fails to take into account pharmacokinetic differences between congeners and the generally acknowledged belief that body burden or some other measure of cumulative dose is more appropriate for estimating the health risk posed by persistent chemicals. The other three dose metrics do account for these important factors, and the corresponding RPFs are at least 10-fold lower than the current TEF for 4-PeCDF. In summary, our analyses support an administered dose TEF no greater than 0.25 and one in the 0.05-0.1 range for internal dose metrics such as lifetime average liver concentration or body burden.     

Enhanced faecal excretion of 2,3,4,7,8-pentachlorodibenzofuran in rats by a long-term treatment with activated charcoal beads

1. The effect of activated charcoal beads on the faecal excretion of 2,3,4,7,8-pentachlorodibenzofuran (PenCDF), a causal agent of yusho, which accumulates in the body, was studied for 12 weeks in rats. 2. Diets supplemented with 1% and 5% activated charcoal beads stimulated faecal excretion of PenCDF about 2- and 4-fold, respectively. The concentration of PenCDF in liver, the major storage site, was decreased significantly and dose-dependently by the treatment. 3. The charcoal bead treatment decreased the extent of fatty liver, thymic atrophy, and induction of hepatic benzo[a]pyrene hydroxylase.     

Characterization of myoglobin toxicity in renal cortical slices from Fischer 344 rats

Rhabdomyolysis is associated with acute renal failure. The following study first characterized myoglobin in vitro toxicity using renal cortical slices isolated from male Fischer 344 rats. This model provided interaction between various cells within the nephron and provides myoglobin access predominantly through the basolateral membrane. Second, this study examined the effect of deferoxamine (DFX) and glutathione on myoglobin toxicity to determine the role of radicals and iron. Renal cortical slices were incubated for 30-120 min with 0, 4, 10 or 12 mg/ml myoglobin. Myoglobin was pretreated with 4 mM ascorbic acid prior to addition to the slices to ensure that myoglobin was in its reduced state. In other experiments tissues were pretreated for 15 min with 0.1 mM of the iron chelator DFX or 30 min with 1 mM glutathione prior to co-incubation with myoglobin. Finally, slices were pretreated with 1 mM glutathione for 30 min, rinsed and incubated only with myoglobin. Early event changes occurred within a 60 min exposure and included a decline in pyruvate-stimulated gluconeogenesis, increased lipid peroxidation levels and decreased glutathione levels. Loss of ATP levels and increased lactate dehydrogenase (LDH) release required a 120 min exposure to myoglobin. DFX reduced myoglobin induced effects on LDH leakage but had no effect on gluconeogenesis suggesting that myoglobin toxicity had an iron dependent (LDH) and independent (gluconeogenesis) pathway. Pretreatment with glutathione provided complete protection and was mediated by intracellular events.     

Characterization of myoglobin toxicity in renal cortical slices from Fischer 344 rats

Rhabdomyolysis is associated with acute renal failure. The following study first characterized myoglobin in vitro toxicity using renal cortical slices isolated from male Fischer 344 rats. This model provided interaction between various cells within the nephron and provides myoglobin access predominantly through the basolateral membrane. Second, this study examined the effect of deferoxamine (DFX) and glutathione on myoglobin toxicity to determine the role of radicals and iron. Renal cortical slices were incubated for 30-120 min with 0, 4, 10 or 12 mg/ml myoglobin. Myoglobin was pretreated with 4 mM ascorbic acid prior to addition to the slices to ensure that myoglobin was in its reduced state. In other experiments tissues were pretreated for 15 min with 0.1 mM of the iron chelator DFX or 30 min with 1 mM glutathione prior to co-incubation with myoglobin. Finally, slices were pretreated with 1 mM glutathione for 30 min, rinsed and incubated only with myoglobin. Early event changes occurred within a 60 min exposure and included a decline in pyruvate-stimulated gluconeogenesis, increased lipid peroxidation levels and decreased glutathione levels. Loss of ATP levels and increased lactate dehydrogenase (LDH) release required a 120 min exposure to myoglobin. DFX reduced myoglobin induced effects on LDH leakage but had no effect on gluconeogenesis suggesting that myoglobin toxicity had an iron dependent (LDH) and independent (gluconeogenesis) pathway. Pretreatment with glutathione provided complete protection and was mediated by intracellular events.     

Metabolism of dimethylamine in the nasal mucosa of the Fischer 344 rat

The metabolism of dimethylamine (DMA) in the nasal mucosa of the male Fischer 344 rat was investigated in vitro and in vivo. Microsomes were prepared from liver, and from respiratory and olfactory nasal mucosa. All microsomal preparations metabolized DMA to formaldehyde (CH2O), though DMA was a poor substrate for the N-demethylation reaction when compared to benzphetamine. Phenobarbital-induced microsomes metabolized DMA at a rate less than that of control. The results indicated that DMA was a substrate for both cytochrome P-450 and FAD-containing monooxygenase, and that both enzyme activities were present in all microsomal preparations. Finally, unextractable radioactivity was observed in DNA, RNA, and protein isolated from respiratory and olfactory mucosa of rats exposed to either 10 or 175 ppm of [14C]DMA, suggesting metabolism of [14C]DMA to 14CH20 with subsequent incorporation of 14C into macromolecules. The results demonstrate that the respiratory and olfactory nasal mucosa have the capability to metabolize DMA to CH2O, and indicate that such metabolism occurs in vivo.